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Abstract
Background: SNP rs5770917 located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype were previously
identified as susceptibility loci for narcolepsy with cataplexy. This study was conducted in order to investigate whether
these genetic markers are associated with Japanese CNS hypersomnias (essential hypersomnia: EHS) other than narcolepsy
with cataplexy.
Principal Findings: EHS was significantly associated with SNP rs5770917 (Pallele=3.6610
23; OR=1.56; 95% c.i.: 1.12–2.15)
and HLA-DRB1*1501-DQB1*0602 haplotype (Ppositivity=9.2610
211; OR=3.97; 95% c.i.: 2.55–6.19). No interaction between the
two markers (SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype) was observed in EHS.
Conclusion: CPT1B, CHKB and HLA are candidates for susceptibility to CNS hypersomnias (EHS), as well as narcolepsy with
cataplexy.
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Introduction
We previously reported that SNP rs5770917 located between
the carnitine palmitoyltransferase 1B (CPT1B) and choline kinase
beta (CHKB) genes was associated with susceptibility to narcolepsy
with cataplexy after performing a genome-wide association study
in Japanese and Korean populations (P=1.4610
27; odds
ratio=1.68) [1]. In addition, significantly lower levels of both
CPT1B and CHKB mRNA expression were observed in hetero-
zygotes (TC) with the risk allele, as compared to homozygotes (TT)
with the major allele [1]. Moreover, it is noteworthy that all
narcoleptic patients with cataplexy in Japan carry a human
leukocyte antigen (HLA)-DRB1*1501-DQB1*0602 haplotype [2,3].
Similar findings have been confirmed in individuals of European
and African decent for whom the association is with DQB1*0602.
[3,4].
Central nervous system (CNS) hypersomnias other than
narcolepsy with cataplexy are also complex disorders. Both genetic
and environmental factors may contribute to the development of
CNS hypersomnias, as in the case of narcolepsy with cataplexy
[5,6]. Identification of the genetic factors has been challenging
because of the low prevalence and the difficulty of diagnosis [5,6].
Although several reports have confirmed the association between
some CNS hypersomnias and HLA, HLA typing was performed at
the low-resolution serological level, and the association showed
marginally statistical significance (0.01,P,0.05) because the
number of cases was small [6–9]. Thus, in this study, we extended
previous association studies to essential hypersomnia (EHS), which
is a group of other CNS hypersomnias similar to narcolepsy with
cataplexy in the symptom of excessive daytime sleepiness. Our
diagnostic criteria for EHS comprised three clinical items: 1)
recurrent daytime sleep episodes that occur basically every day
over a period of at least 6 months; 2) absence of cataplexy; 3) the
condition does not meet the diagnostic criteria of any other
disorder causing excessive daytime sleepiness, such as sleep-apnea
syndrome [9,10]. EHS is heterogeneous and consists of several
CNS hypersomnias from aborted form of narcolepsy with
cataplexy, narcolepsy without cataplexy and a part of idiopathic
hypersomnia without long sleep time if we employed International
Classification of Sleep Disorders 2
nd edition criteria (AASM 2005).
Our diagnostic criteria for EHS are focused on the daytime
clinical characteristics of CNS hypersomnias [9,10]. A case-control
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rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype are
associated with EHS.
Methods
Cases of EHS (n=137) and Controls (n=569) were unrelated
Japanese living in Tokyo or neighboring areas. Written informed
consent was obtained from participants, and the study was
approved by the local institutional review boards of all
collaborative organizations. Our diagnostic criteria for EHS
comprised three clinical items: 1) recurrent daytime sleep episodes
that occur basically every day over a period of at least 6 months; 2)
absence of cataplexy; 3) the condition does not meet the diagnostic
criteria of any other disorder causing excessive daytime sleepiness,
such as sleep-apnea syndrome [9,10].
Genotyping for SNP rs5770917 in cases was performed using
Taqman genotyping assays. For controls, we used the genotype
data from the previous genome-wide association study for
narcolepsy with cataplexy [1]. Genotyping for HLA-DRB1 and
HLA-DQB1 in cases was performed by Luminex Multi-Analyte
Profiling system (xMAP) with a WAKFlow HLA typing kit
(Wakunaga, Hiroshima, Japan). Briefly, target DNA was amplified
by polymerase chain reaction (PCR) with biotinylated primers.
The PCR amplicon was then denatured and hybridized to
complementary oligonucleotide probes immobilized on fluorescent
coded microsphere beads. At the same time, biotinylated PCR
products were labeled with phycoerythrin-conjugated streptavidin
and immediately examined with Luminex 100 (Luminex, Austin,
TX). We did not perform HLA-typing in controls, instead we
utilized HLA-DRB1 and HLA-DQB1 frequency data obtained from
Japanese Society for Histocompatibility and Immunogenetics
databank (a total of 516 Japanese general population were
genotyped) (http://jshi.umin.ac.jp/mhc/mhc_vol06-10/v08naka-
jima_all.pdf).
The observed associations of SNP rs5770917 and HLA-
DRB1*1501-DQB1*0602 haplotype were assessed by comparing
frequency differences between cases and controls using chi-
squared test. Population attributable risk percentage (PAR) for
the risk genotypes (SNP rs5770917 C/C and T/C) was evaluated
using the following formula, PAR=[p(RR–1)]/[p(RR–1)+1]),
where p is calculated based on genotype frequencies in healthy
controls and RR indicates relative risk of the risk genotypes. Odds
ratio (OR) of the risk genotypes is similar to RR because of the low
prevalence of EHS and narcolepsy with cataplexy. Interactions
between the two markers (SNP rs5770917 and HLA-DRB1*1501-
DQB1*0602 haplotype) were calculated based on the positivity of
each risk allele in EHS using the correlation coefficient.
Results
In order to investigate whether SNP rs5770917 is also a genetic
risk marker for the development of EHS, the SNP was genotyped
in 137 cases and 569 controls. We found a significant difference
between cases and controls (Pallele=3.6610
23; OR=1.56; 95%
c.i.: 1.12–2.15) (Table 1). Significant deviation from Hardy-
Weinberg equilibrium (HWE) was not observed in either cases or
controls. To estimate the epidemiological significance of SNP
rs5770917 for EHS development in the Japanese population, PAR
was found to be 14.2% in our Japanese samples (Table 2).
We also conducted an association study for HLA-DRB1*1501-
DQB1*0602 haplotype. Cases carried a significantly higher
frequency of HLA-DRB1*1501-DQB1*0602 haplotype than the
Japanese general population (Ppositivity=9.2610
211; OR=3.97;
95% c.i.: 2.55–6.19) (Table 3).
The interaction between these two markers (SNP rs5770917
and HLA-DRB1*1501-DQB1*0602 haplotype) was then calculated
in EHS. No significant interaction was found (P=0.20; r
2=0.01),
thus suggesting that these markers independently affect suscepti-
bility to EHS.
Discussion
In the present study, SNP rs5770917, which was identified in
our previous genome-wide association study of narcolepsy with
cataplexy [1], was also found to confer susceptibility to EHS, a
group of other CNS hypersomnias similar to narcolepsy with
cataplexy. Thus, the SNP is considered to be a common risk
marker for CNS hypersomnias in general. Nevertheless, the OR
for narcolepsy with cataplexy (1.92) was greater than that for EHS
(1.57) (Table 2). Moreover, PAR for narcolepsy with cataplexy
Table 1. Frequency of SNP rs5770917 in Japanese cases and
controls.
SNP rs5770917
HWE
P RAF
OR
(95% c.i.) Pallele
CC (%) TC (%) TT (%)
Case 8 (5.8%) 46
(33.6%)
83
(60.6%)
0.631 22.6% 1.56
(1.12–2.15)
3.6610
23
Control 13 (2.3%) 154
(27.1%)
402
(70.7%)
0.697 15.8%
Pallele was calculated by comparing allele frequency differences in SNP
rs5770917 between cases and controls using chi-squared test (one-tailed test).
RAF, risk allele frequency (C allele); OR, odds ratio; 95% c.i., confidence interval.
HWE P represents P value from chi-squared test for Hardy-Weinberg
equilibrium.
doi:10.1371/journal.pone.0005394.t001
Table 2. Population attributable risk in SNP rs5770917.
SNP rs5770917 OR (95% c.i.) PAR
C+ (%) C2 (%)
EHS 54 (39.4%) 83 (60.6%) 1.57(1.06–2.31) 14.2%
Narcolepsy with
cataplexy
169 (44.4%) 212 (55.6%) 1.92(1.46–2.52) 21.2%
EHS, essential hypersomnia; OR, odds ratio; 95% c.i., confidence interval; PAR,
population attributable risk.
doi:10.1371/journal.pone.0005394.t002
Table 3. Positivity for HLA-DRB1*1501-DQB1*0602 haplotype.
HLA-DRB1*1501-DQB1*0602
haplotype OR (95% c.i.) Ppositivity
+ (%) 2 (%)
Case 47 (34.3%) 90 (65.7%) 3.97 (2.55–6.19) 9.2610
211
Control 60 (11.6%) 456 (88.4%)
Ppositivity was calculated by comparing the differnce in positivity for HLA-
DRB1*1501-DQB1*0602 haplotype between cases and controls using chi-
squared test (one-tailed test).
OR, odds ratio; 95% c.i., confidence interval.
doi:10.1371/journal.pone.0005394.t003
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the risk allele frequency of the SNP in narcolepsy with cataplexy
(25.2%) was greater than that in EHS (22.6%) (Table 1) [1].
CPT1B is the rate-controlling enzyme of long-chain fatty acid
b-oxidation in muscle mitochondria. CPT1B catalyzes the
transport of long-chain fatty acyl-CoAs from the cytoplasm into
the mitochondria through the carnitine shuttle [11]. Several
reports have indicated the role of fatty acid b-oxidation and
carnitine system in sleep regulation. First, fasted juvenile visceral
steatosis (jvs
2/2) mice with systemic carnitine deficiency exhibit a
higher frequency of fragmented wakefulness and rapid eye
movement (REM) sleep, and reduced locomotor activity [12,13].
These phenotypes in fasted jvs
2/2 mice are similar to those in
mouse models of narcolepsy [14,15]. Moreover, fasted jvs
2/2 mice
are activated by modafinil, which is used for the treatment of
human narcolepsy [12]. Second, mice deficient in short-chain
acyl-CoA dehydrogenase (encoded by Acads), an enzyme
catalyzing the first step of b-oxidation, have shown significantly
slower theta frequency during REM sleep [16]. Administration of
acetyl-L-carnitine, which is known to restore b-oxidation in the
mitochondria, significantly recovers slow theta frequency in
mutant mice [16].
CHKB catalyzes the first phosphorylation reaction in the CDP-
choline pathway for phosphatidylcholine synthesis [17]. Phospha-
tidylcholine is the major membrane phospholipid in mammalian
cells [18] and inhibition of phosphatidylcholine synthesis triggers
apoptosis in the brain [19]. CDP-choline, which is used in the
treatment of disorders of a cerebrovascular nature [20], increases
acetylcholine release [21]. Acetylcholine is a known REM- and
wake-promoting neurotransmitter that increases narcolepsy symp-
toms [22]. Thus, either of these two genes (CPT1B and CHKB)i sa
plausible candidate for susceptibility to CNS hypersomnias (EHS),
as well as narcolepsy with cataplexy.
To date, reports on the association between HLA and CNS
hypersomnias other than narcolepsy with cataplexy have been
based on serological typing and small sample size, thus yielding
only marginal statistical significance [6–9]. In this study, we found
a highly significant association between HLA and EHS using
DNA-based high-resolution typing (Ppositivity=9.2610
211), sug-
gesting an immunological pathogenesis for EHS.
It is important to examine the interaction between SNP
rs5770917 and HLA with regard to susceptibility to CNS
hypersomnias. However, it is impossible to calculate the
interaction between SNP rs5770917 and HLA in narcolepsy with
cataplexy, because almost all patients possess HLA-DRB1*1501-
DQB1*0602 haplotype. No interaction was observed between SNP
rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype, suggest-
ing that they are independent risk factors for not only EHS but
also narcolepsy with cataplexy.
EHS analyzed in this study have recurrent daytime sleep
episodes but do not have cataplexy. Thus, SNP rs5770917 located
between CPT1B and CHKB might be involved in the pathogenesis
of excessive daytime sleepiness, not cataplexy. Although our cases
are heterogeneous, as exemplified by the findings that not all
patients with EHS carry HLA-DRB1*1501-DQB1*0602 haplotype,
SNP rs5770917 is considered to be a common risk marker for both
HLA positive and negative EHS, because no interaction was
observed between SNP rs5770917 and HLA-DRB1*1501-
DQB1*0602 haplotype.
Our data suggest that EHS, a group of heterogeneous CNS
hypersomnias similar to narcolepsy with cataplexy, might be in
continuity with narcolepsy with cataplexy in common genetic
background.
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